Breast Cancer Clinical Trials in Seattle

Showing 201-220 of 334 trials

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658

This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.

Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic MutationTriple-Negative Breast Cancer

University of Washington

Seattle, Washington, United States

COMPLETEDPhase 3< 1 mile

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

NCT01492101

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.

Locally Recurrent Breast CancerMetastatic Breast Cancer

Nektar Therapeutics852 participantsStarted Dec 2011

Flagstaff, Arizona, United States • Burbank, California, United States • Los Angeles, California, United States +150 more locations

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Breast Cancer Trials in Other Cities

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Vaccine Therapy in Treating Patients With Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Other Conditions in Seattle